THIRD PRIMARY or any BOOSTER DOSE COVID VACCINATION -GUIDANCE FOR MANAGING ADULT PATIENTS WHO HAVE A HISTORY **OF ALLERGIC REACTIONS**

Reactions may occur despite pre-medication

Has the patient had a previous Comirnaty / Spikevax (mRNA) vaccine? Yes Proceed with No Allergic reaction to Comirnaty /Spikevax? No vaccination PATIENT CHARACTERISTICS PATIENT CHARACTERISTICS PATIENT CHARACTERISTICS Yes History of immediate Diagnosis of PEG allergy Previous allergic reaction (including anaphylaxis¹ to multiple confirmed by Allergy Service PATIENT anaphylaxis¹) to a food, insect sting PATIENT drugs, a vaccine or idiopathic and most medicines. **CHARACTERISTICS CHARACTERISTICS** anaphylaxis or anaphylaxis suspected due to PEG Is there a contraindication Family history of allergies Symptoms of anaphylaxis¹ Immediate Non-anaphylactic containing medication to Novavax vaccine? within 2 hours of previous or delaved or mastocytosis **Previous Non-Systemic** Comirnaty/Spikevax (>2 hours) symptoms to reaction to non COVID vaccine **Refer** to NUH Allergy vaccination vaccination triage for advice on No Yes Hypersensitivity to non-steroidal COVID vaccination anti-inflammatory drugs Tolerated last **Reaction** to last e.g. aspirin, ibuprofen dose of dose? nuhnt.nuhvaccine@ Comirnaty / **Refer** for Novavax nhs.net Chronic Spontaneous / Idiopathic Spikevax vaccine -Urticaria (CSU) hospital hub sites SYMPTOMS OF ANAPHYLAXIS¹ Give Patients will need to • sudden onset and rapid progression of symptoms Give Comirnaty/Spikevax be consented by • life-threatening airway and/or breathing and/or circulation Comirnaty/Spikevax vaccine in any setting onsite prescriber, for Proceed with problems vaccine in hospital individual risk based Pre-dose with non-• skin and/or mucosal changes (flushing, urticaria, angioedema) Comirnaty/Spikevax setting sedating discussion. vaccination in any setting. See with features above Pre-dose with nonantihistamine* Observe for 30 • There can also be gastrointestinal symptoms (e.g. vomiting, Green Book guidelines. sedating and check baseline minutes **Observe for 15 minutes** abdominal pain, incontinence) antihistamine* observations CSU patients can pre-dose with and check baseline **Observe for 30 mins** non-sedating antihistamine' observations * Suggested adult pretreatment regimen: Observe for 60 mins Cetirizine 20mg 30mins prior to vaccine then continue Cetirizine 10mg BD for 3 days or Integrated **We Lister** Department of Clinical Immunology and Allergy longer if required (NB: off label dose)

KH – 15th September 2022 Version12

Nottingham

NHS Trust

University Hospitals

We Care





REFERENCES

1. Green Book, V4_0, Chapter 8- Vaccine safety and the management of adverse events following immunisation, p58

Anaphylaxis is likely when all of the following three criteria are met:

- sudden onset and rapid progression of symptoms
- life-threatening airway and/or breathing and/or circulation problems
- skin and/or mucosal changes (flushing, urticaria, angioedema).

THE FOLLOWING SUPPORTS THE DIAGNOSIS:

exposure to a known allergen where the patient is already known to be allergic.

REMEMBER:

- skin or mucosal changes alone are not a sign of an anaphylactic reaction
- skin and mucosal changes can be subtle or absent in up to 20% of reactions (some patients can have only a decrease in blood pressure, i.e. a circulation problem)

•there can also be gastrointestinal symptoms (e.g. vomiting, abdominal pain, incontinence).

Most anaphylactic reactions occur in individuals who have no known risk factors.

REFERRALS:

- NUH Allergy referral form available on Nottinghamshire APC website; send to nuhnt.nuhvaccine@nhs.net
- NUH Hospital Hub and SFHFT KMH Hospital Hub for vaccination in hospital settings & alternative vaccines with <u>confirmed</u> NUH Allergy advice.

ACKNOWLEDGEMENT

Extension to flowchart devised by BSACI and published in the Green Book Chapter 14a COVID-19 – SARS-COV-2



